Pharm

Abciximab

search

Abciximab, ReoPro

  • See Also
  1. Glycoprotein IIB/IIIA Inhibitor
  2. Tirofiban
  3. Eptifibatide
  • Indications
  1. Non-Q-Wave Myocardial Infarction
  2. High risk Unstable Angina
  3. Percutaneous Coronary Intervention (PCI)
  • Contraindications
  1. Recent major bleeding
  • Mechanism
  1. Fab Antibody fragment
  2. Inhibits Platelet aggregation via Glycoprotein IIb/IIIa receptors on Platelet plasma membranes
  3. Inhibits Fibrinogen binding to Platelets
  • Dosing
  1. Percutaneous Coronary Intervention (PCI)
    1. Load: 0.25 mg/kg IV bolus given 10 to 60 minutes before PCI
    2. Infuse: 0.125 mcg/kg/min up to 10 mcg/min IV for 12 hours
  2. Unstable Angina or non-ST-elevation Myocardial Infarction pending PCI within 24 hours
    1. Dosing as for PCI, with infusion up to 18 to 24 hours, completing at one hour post-PCI
  3. Coronary Aneursym in Kawasaki Disease
    1. Off label use for age >2 months old
    2. Dosing as used in PCI
  • Safety
  1. Unknown safety in pregnancy
  2. Unknown safety in Lactation
    1. Abciximab is excreted in human milk
  • Resources
  1. Abciximab (FDA)
    1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103575s5318lbl.pdf
  2. Stoffer (2022) Abciximab, StatPearls, Treasure Island
    1. https://www.ncbi.nlm.nih.gov/books/NBK482195/